Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Liver cancer, adult primary
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 84 for your search:
Start Over
Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-213, NCI-2013-01103, NCT01849588
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: HCC-P3-11-01, NCI-2011-03569, NCT01387932
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-103, NCI-2012-01029, NCT01556490
Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 1112, NCI-2012-02057, NCT01730937
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ARQ197-A-U303, NCI-2013-00021, NCT01755767
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 15982, NCI-2013-01156, 2012-003649-14, NCT01774344
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: XL184-309, NCI-2013-02092, NCT01908426
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PIN-PHO1201, NCI-2014-02418, NCT02082522
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 104-13-302, NCI-2014-02527, NCT02112656
Vaccine Therapy in Treating Patients With Liver Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: 04-101, NCI-2011-02468, NCT00669136
TRC105 and Sorafenib Tosylate in Treating Patients with Liver Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0102, NCI-2013-01477, 110102, 339029, P10766, NCT01306058
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Tivozanib in Treating Patients with Liver Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 229112, NCI-2013-00756, NCT01835223
Hydroxychloroquine Sulfate with TACE in Treating Patients with Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 22213, NCI-2014-00398, 818625, NCT02013778
Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A041-05, NCI-2014-01930, ACE-041, NCT02024087
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S4-13-001, NCI-2015-00637, NCT02128282
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TKM-HCC-001, NCI-2015-00970, NCT02191878
Ipilimumab and Hypofractionated Stereotactic Body Radiation Therapy in Treating Patients with Advanced Solid Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0882, NCI-2015-00042, NCT02239900
Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG221-C-003, NCI-2015-01170, NCT02273739
Start Over